Lantheus Holdings, Inc. (NASDAQ:LNTH) is a company that focuses on diagnostic and therapeutic radiopharmaceuticals. It plays a significant role in the healthcare sector by providing essential products for medical imaging and treatment. The company faces competition from other firms in the radiopharmaceutical industry, but it continues to strive for growth and innovation.
On August 11, 2025, Richard Newitter from Truist Financial set a price target of $63 for LNTH. At that time, the stock price was $56.07, suggesting a potential increase of about 12.36%. This optimistic outlook comes despite recent financial challenges faced by the company, as highlighted in their Q2 2025 earnings call.
During the Q2 2025 earnings call, Lantheus reported a 4% decline in revenue, with GAAP revenue at $378 million, missing analyst expectations of $387.94 million. The adjusted earnings per share (EPS) was $1.57, below the consensus estimate of $1.68. These figures indicate a decline compared to the previous year, with GAAP revenue down 4.1% and adjusted EPS down 12.8%.
In light of these results, Lantheus revised its full-year financial outlook for FY2025. The company lowered its revenue guidance to a range of $1.475 billion to $1.51 billion and adjusted EPS guidance to between $5.50 and $5.70. This adjustment reflects challenges in its PYLARIFY prostate cancer diagnostic business and a reassessment of growth expectations.
Despite the softer operational performance, Lantheus is working on diversifying its portfolio and investing in future growth opportunities. The current stock price of LNTH is $56.07, reflecting a decrease of approximately 1.98%. The stock has fluctuated between a low of $54.79 and a high of $57.12 today, with a market capitalization of about $3.81 billion.
